| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790264 | Urologic Oncology: Seminars and Original Investigations | 2017 | 8 Pages |
Abstract
HFI was demonstrated for the first time to be an independent poor prognostic factor. Its potential role in predicting resistance to antiangiogenic therapy warrants further investigation.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Solène-Florence M.D., Ph.D., Angelique M.D., Karim M.D., Ph.D., Boris M.D., Mathilde Ph.D., Sahar M.D., Ph.D., Alain M.D., Ph.D., Frantz M.D., Mokrane M.D., Gregory M.D., Ph.D., Benoit M.D., Romain M.D., Alexandra Ph.D., Jean PharmD, Ph.D., Julien M.D.,